VERACYTE INC (VCYT)

Is NASDAQ:VCYT a Fit for high Growth Investing Strategies?

Should you consider VERACYTE INC (NASDAQ:VCYT) for high growth investing?

First Week of January 2025 Options Trading For Veracyte (VCYT)

Veracyte Announces Third Quarter 2024 Financial Results

Veracyte to Participate in Upcoming Investor Conferences

Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024

New Data Presented at ASTRO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men

Tempus AI Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating

A Relative Strength Rating upgrade for Tempus AI shows improving technical performance.

New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors

Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle

First Week of October 18th Options Trading For Veracyte (VCYT)

Thermo Fisher Scientific Stock Sees RS Rating Jump To 81

Thermo Fisher Scientific stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 77 to 81.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Pre-market stock movers are a hot topic on Wednesday and we have all of the latest news traders need to know about them this morning!

VCYT Stock Earnings: Veracyte Beats EPS, Beats Revenue for Q2 2024

VCYT stock results show that Veracyte beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

VCYT Stock Earnings: Veracyte Beats EPS, Beats Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Veracyte (NASDAQ:VCYT) just reported results for the second quarter of 2024.Ver...

Veracyte Announces Second Quarter 2024 Financial Results

The 3 Best Personalized Nutrition Stocks to Buy Now

Explore personalized nutrition stocks capitalizing on AI, machine learning and genetic profiling to provide targeted dietary solutions.

Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024

Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors

Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer

July 19th Options Now Available For Veracyte (VCYT)

Veracyte to Participate in Upcoming Investor Conferences

VCYT Stock Earnings: Veracyte Beats EPS, Beats Revenue for Q1 2024

VCYT stock results show that Veracyte beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

VCYT Stock Earnings: Veracyte Beats EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Veracyte (NASDAQ:VCYT) just reported results for the first quarter of 2024.Vera...

Veracyte Announces First Quarter 2024 Financial Results

14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding

Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024

New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance

Veracyte Becomes Oversold (VCYT)

Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024

Commit To Buy Veracyte At $12.50, Earn 16% Annualized Using Options